Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

68.28
11,965,096

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

Dow Hits New All-Time High Close as Rescue Bill Passes

Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.

BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.

VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study

VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

Sweta Killa headshot

5 Beaten-Down Stocks of Nasdaq ETF With Upside Potential

We highlighted five stocks from the ETF that were hit badly in the tech rout but might reverse the trend, given their solid Zacks Rank #1 (Strong Buy) or 2 (Buy) and positive earnings estimate revisions in a month.

Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains

Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.

Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II

Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.

IBM & Moderna Partner to Augment COVID-19 Vaccine Management

IBM and Moderna (MRNA) team up to explore utility of hybrid cloud and blockchain technology to enhance COVID-19 vaccine management and stem the spread of the contagion.

Kevin Cook headshot

Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?

New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.

USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?

USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Rimmi Singhi headshot

5 High Earnings Yield Picks That Command Your Attention

Level up your portfolio with high earnings yield stocks including ArcelorMittal (MT), Moderna, (MRNA), Shell (RDS.A), Magna (MGA), Winnebago (WGO).

Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply

Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates

Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca

The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca

Panel Of Zacks Experts headshot

Top Stock Picks for Week of March 1, 2021

A Leader in Covid-19 Vaccine and a Company Showing Positivity.

Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit

Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.

Kinjel Shah headshot

FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition

J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.

Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall

Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

Sanghamitra Saha headshot

Nasdaq ETF's Worst Day Since October: Stocks That Survived

The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.

Mark Vickery headshot

Jobless Claims, Q4 GDP Dip; Durable Goods Soar +3.4%

While jobless claims fell on weather-related issues, Durable Goods were up big for January.

Economic Data Deluge

Economic Data Deluge

Moderna (MRNA) Misses on Q4 Earnings, Eyes $18B in Vaccine Sales

Moderna (MRNA) records product sales for the first time which comprises sales of its coronavirus vaccine, mRNA-1273. Stock up.